News

Filter

Current filters:

Merck & Co

201 to 210 of 96529 results

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

Lilly to drop Ph III tabalumab trial in lupus due to poor efficacy

02-10-2014

US pharma major Eli Lilly has said it will discontinue development of tabalumab, which is being studied…

Anti-Arthritics/RheumaticsEli LillyImmunologicalsPharmaceuticalResearchtabalumabUSA

Incyte earns $60 million milestone on European reimbursement for Jakavi

Incyte earns $60 million milestone on European reimbursement for Jakavi

02-10-2014

US biopharma company Incyte says that it has earned a $60 million milestone payment from Swiss pharma…

BiotechnologyEuropeFinancialIncyteJakafiJakaviNovartisOncologyPricing

Supernus sues Actavis for Trokendi XR patents infringement

Supernus sues Actavis for Trokendi XR patents infringement

02-10-2014

USA-based specialty drug firm Supernus Pharmaceuticals says it has sued generic drugmaker Actavis and…

ActavisGenericsLegalNeurologicalPatentsSupernus PharmaceuticalsTrokendi XRUSA

Denmark’s Forward Pharma plans IPO

Denmark’s Forward Pharma plans IPO

02-10-2014

Denmark-based Forward Pharma A/S today announced it has commenced an underwritten initial public offering…

BiotechnologyDenmarkFinancialForward PharmaImmunologicals

Intrexon and Amneal in second product collaboration

Intrexon and Amneal in second product collaboration

02-10-2014

US synthetic biology specialist Intrexon and privately-held generics drugmaker Amneal Pharmaceuticals…

Amneal PharmaceuticalsGenericsIntrexonLicensingProductionUSA

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

02-10-2014

UK biotech firm Oxford BioTherapeutics and family-owned Italian Berlin Chemie/Menarini Group have designated…

BiotechnologyItalyMenariniOncologyOxford BioTherapeuticsResearchUK

Report: HER2-positive breast cancer market could treble in USA by 2023

Report: HER2-positive breast cancer market could treble in USA by 2023

02-10-2014

The US treatment market for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer…

HerceptinMarkets & MarketingOncologyPharmaceuticalRocheUSA

Relmada appoints Julie Chen as Director of Finance and Operations

02-10-2014

US pain therapeutic specialists Relmada Therapeutics has appointed Julie Chen as its Director of Finance…

AnalgesiaBoardroomPharmaceuticalRelmada TherapeuticsUSA

Zynerba Pharmaceuticals announces CEO and president

Zynerba Pharmaceuticals announces CEO and president

02-10-2014

USA-based specialty pharmaceutical company Zynerba Pharmaceuticals, focused on innovative transdermal…

BoardroomDermatologicalsPharmaceuticalUSAZynerba Pharmaceuticals

201 to 210 of 96529 results

Parexel

Parexel

Back to top